284 related articles for article (PubMed ID: 25833198)
21. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
22. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
24. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M
Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326
[TBL] [Abstract][Full Text] [Related]
25. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
Ma Y; Wink M
Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284
[TBL] [Abstract][Full Text] [Related]
26. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
27. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
28. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
29. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
30. ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Cell Oncol (Dordr); 2017 Dec; 40(6):631-638. PubMed ID: 28677036
[TBL] [Abstract][Full Text] [Related]
31. Modulation of ABCC1 and ABCG2 proteins by ouabain in human breast cancer cells.
DA Silva VA; DA Silva KA; Delou JM; DA Fonseca LM; Lopes AG; Capella MA
Anticancer Res; 2014 Mar; 34(3):1441-8. PubMed ID: 24596392
[TBL] [Abstract][Full Text] [Related]
32. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
Yuan J; Lv H; Peng B; Wang C; Yu Y; He Z
Cancer Chemother Pharmacol; 2009 May; 63(6):1103-10. PubMed ID: 18820913
[TBL] [Abstract][Full Text] [Related]
33. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
34. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
Pinzón-Daza ML; Cuellar-Saenz Y; Nualart F; Ondo-Mendez A; Del Riesgo L; Castillo-Rivera F; Garzón R
J Cell Biochem; 2017 Jul; 118(7):1868-1878. PubMed ID: 28106284
[TBL] [Abstract][Full Text] [Related]
35. Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.
Hermawan A; Wagner E; Roidl A
Oncol Rep; 2016 Mar; 35(3):1732-40. PubMed ID: 26708059
[TBL] [Abstract][Full Text] [Related]
36. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
37. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.
Rigalli JP; Scholz PN; Tocchetti GN; Ruiz ML; Weiss J
Eur J Nutr; 2019 Feb; 58(1):139-150. PubMed ID: 29101532
[TBL] [Abstract][Full Text] [Related]
38. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
40. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Xie Y; Nakanishi T; Natarajan K; Safren L; Hamburger AW; Hussain A; Ross DD
Biochim Biophys Acta; 2015 Mar; 1849(3):317-27. PubMed ID: 25615818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
